WHO has updated its living guidelines on COVID-19 therapeutics. The ninth update released on 03 March 2022 include a conditional recommendation on molnupiravir.
Molnupiravir has...
Molnupiravir, the world’s first oral drug (approved by MHRA, UK) against COVID-19 along with upcoming drugs such as Paxlovid and sustained vaccination drive has raised hopes...
TMPRSS2 is an important drug target to develop anti-viral drugs against COVID-19. MM3122 is a lead candidate that has shown promising result in vitro and in...
Molnupiravir, a nucleoside analog of cytidine, a drug that has shown excellent oral bioavailability and promising results in Phase 1 and Phase 2 trials, could prove...
The plant derived agent, Thapsigargin (TG) has been used in traditional medicine for long time. TG has shown promises as a potential anti-cancer drug because of its...
Recent study has developed a new potential broad-spectrum drug for treating infections from Herpes Simplex Virus-1 and possibly other viruses in both new patients...